What is the Role of Real-World Data in Metastatic Renal Cell Cancer?
- 11 August 2021
- journal article
- editorial
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (30) , 3905-3909
Abstract
No abstract availableKeywords
Funding Information
- Institutional research funding from Roche
This publication has 26 references indexed in Scilit:
- Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trialThe Lancet Oncology, 2016
- Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy eraUrologic Oncology: Seminars and Original Investigations, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialThe Lancet Oncology, 2015
- Improving Clinical Trial Recruitment: Experience of a Tertiary Renal Oncology CentreOncology, 2013
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapyKidney International, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Brain metastasis from renal cell carcinomaCancer, 2008
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 1999